JPH04164098A - Chemically modified granulocyte colony stimulating factor derivative - Google Patents

Chemically modified granulocyte colony stimulating factor derivative

Info

Publication number
JPH04164098A
JPH04164098A JP41895390A JP41895390A JPH04164098A JP H04164098 A JPH04164098 A JP H04164098A JP 41895390 A JP41895390 A JP 41895390A JP 41895390 A JP41895390 A JP 41895390A JP H04164098 A JPH04164098 A JP H04164098A
Authority
JP
Grant status
Application
Patent type
Prior art keywords
chemically modified
amino acid
cys
glycol
obtain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP41895390A
Inventor
Masatoshi Ishikawa
Shigeru Matsuki
Yuji Okada
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Abstract

PURPOSE: To obtain the chemically modified subject protein with extended blood retention time and long-lasting pharmacological activity, by linking polyeth ylene glycol to a human G-CSF polypeptide derivative wherein Cys at the 17-po sition is substituted by other amino acids.
CONSTITUTION: A polypeptide having the amino acid sequence of the formula (Xaa is an amino acid residue except Cys; Met may further be bonded to the tip of the N-terminal) which has been produced by a transformant obtained by transforming a host such as E. coli, animal cell, etc., in gene recombinant technique and has been separated and purifed, is reacted with an activated polyethylene glycol, e.g. methoxypolyethylene glycol succinidimylsuccinate, thereby to obtain the objective chemically modified protein. Example of the amino acid except Cys is preferably Ala and it is preferred to use polyethylene glycol with a molecular weight of 4,000-20,000. The resultant modified product is improved in its thertmostability and the yield in the modification is good.
COPYRIGHT: (C)1992,JPO
JP41895390A 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative Pending JPH04164098A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5629190 1990-03-07
JP41895390A JPH04164098A (en) 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP41895390A JPH04164098A (en) 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative

Publications (1)

Publication Number Publication Date
JPH04164098A true true JPH04164098A (en) 1992-06-09

Family

ID=26397241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP41895390A Pending JPH04164098A (en) 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative

Country Status (1)

Country Link
JP (1) JPH04164098A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010089A1 (en) * 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification of peptide and protein
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
JP2004508044A (en) * 2000-09-08 2004-03-18 マサチューセッツ インスティテュート オブ テクノロジーMassachusetts Institute of Technology G-csf analog compositions and methods
US7947655B2 (en) 1999-01-14 2011-05-24 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7959909B2 (en) 1997-07-14 2011-06-14 Bolder Biotechnology, Inc. Cysteine variants of interferon gamma
US7994124B2 (en) 1997-07-14 2011-08-09 Bolder Biotechnology, Inc. Methods of use of G-CSF cysteine muteins
US8133480B2 (en) 1997-07-14 2012-03-13 Bolder Biotechnology, Inc. Cysteine variants of interleukin-11
US8148500B2 (en) 1997-07-14 2012-04-03 Bolder Biotechnology, Inc. Method of preparing cysteine mutants of human recombinant GM-CSF
US8524655B2 (en) 2004-11-05 2013-09-03 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US8957023B2 (en) 1999-01-14 2015-02-17 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
JP2016037488A (en) * 2014-08-11 2016-03-22 日本化薬株式会社 CHIMERIC PROTEIN HAVING TGFβ INHIBITING FUNCTION

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0785276A1 (en) * 1994-09-29 1997-07-23 Ajinomoto Co., Inc. Modification of peptide and protein
WO1996010089A1 (en) * 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification of peptide and protein
US8618256B2 (en) 1997-07-14 2013-12-31 Bolder Biotechnology Cysteine variants of interferon gamma
US8859497B2 (en) 1997-07-14 2014-10-14 Bolder Biotechnology, Inc. Method of treatment using cysteine mutants of beta interferon
US8748392B2 (en) 1997-07-14 2014-06-10 Bolder Biotechnology Inc. Methods of treatment using cysteine variants of interleukin-11
US7959909B2 (en) 1997-07-14 2011-06-14 Bolder Biotechnology, Inc. Cysteine variants of interferon gamma
US7964184B2 (en) 1997-07-14 2011-06-21 Bolder Biotechnology, Inc. Cysteine variants of interferon-gamma
US7994124B2 (en) 1997-07-14 2011-08-09 Bolder Biotechnology, Inc. Methods of use of G-CSF cysteine muteins
US8133480B2 (en) 1997-07-14 2012-03-13 Bolder Biotechnology, Inc. Cysteine variants of interleukin-11
US8148500B2 (en) 1997-07-14 2012-04-03 Bolder Biotechnology, Inc. Method of preparing cysteine mutants of human recombinant GM-CSF
US9637530B2 (en) 1997-07-14 2017-05-02 Bolder Biotechnology, Inc. Methods of preparing cysteine variants of human recombinant IL-11
US7947655B2 (en) 1999-01-14 2011-05-24 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8957023B2 (en) 1999-01-14 2015-02-17 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
JP2004508044A (en) * 2000-09-08 2004-03-18 マサチューセッツ インスティテュート オブ テクノロジーMassachusetts Institute of Technology G-csf analog compositions and methods
JP4799803B2 (en) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー G-csf analog compositions and methods
US8524655B2 (en) 2004-11-05 2013-09-03 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
JP2016037488A (en) * 2014-08-11 2016-03-22 日本化薬株式会社 CHIMERIC PROTEIN HAVING TGFβ INHIBITING FUNCTION

Similar Documents

Publication Publication Date Title
Speicher et al. Erythrocyte spectrin is comprised of many homologous triple helical segments
Kupper Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations.
Yoshimura et al. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants.
Gearing et al. Production of leukemia inhibitory factor in Escherichia coli by a novel procedure and its use in maintaining embryonic stem cells in culture
Nachman et al. Leucosulfakinin, a sulfated insect neuropeptide with homology to gastrin and cholecystokinin
Baggiolini et al. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.
US4235771A (en) Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US5981709A (en) α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
Low et al. Chemical characterization of thymosin beta 4.
US5464823A (en) Mammalian antibiotic peptides
US5298490A (en) Tetra and penta-peptides useful in regulating the immune system
US4466918A (en) Method of preparing thymosin alpha 1 and derivatives thereof
Zasloff Antibiotic peptides as mediators of innate immunity
Hillyard et al. A molluskivorous Conus toxin: conserved frameworks in conotoxins
US5202415A (en) Insulin precursors
She et al. A novel lectin with potent immunomodulatory activity isolated from both fruiting bodies and cultured mycelia of the edible mushroomVolvariella volvacea
Cha et al. Development of bioadhesives from marine mussels
US4261886A (en) Peptides having thymopoietin-like activity
EP0215126A1 (en) Human granulocyte colony stimulating factor
EP0442724A2 (en) Modified hIL-6
US6143866A (en) Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
EP0422339A1 (en) Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US4395399A (en) Glycopeptides and method for preparing same
US4316890A (en) Peptides and processes for the manufacture thereof
US5585353A (en) Antibiotic peptides containing D-amino acids